Literature DB >> 12393534

Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.

Liguang Chen1, George Widhopf, Lang Huynh, Laura Rassenti, Kanti R Rai, Arthur Weiss, Thomas J Kipps.   

Abstract

We examined isolated leukemia B cells of patients with chronic lymphocytic leukemia (CLL) for expression of zeta-associated protein 70 (ZAP-70). CLL B cells that have nonmutated immunoglobulin variable region genes (V genes) expressed levels of ZAP-70 protein that were comparable to those expressed by normal blood T cells. In contrast, CLL B cells that had mutated immunoglobulin variable V genes, or that had low-level expression of CD38, generally did not express detectable amounts of ZAP-70 protein. Leukemia cells from identical twins with CLL were found discordant for expression of ZAP-70, suggesting that B-cell expression of ZAP-70 is not genetically predetermined. Ligation of the B-cell receptor (BCR) complex on CLL cells that expressed ZAP-70 induced significantly greater tyrosine phosphorylation of cytosolic proteins, including p72(Syk), than did similar stimulation of CLL cells that did not express ZAP-70. Also, exceptional cases of CLL cells that expressed mutated immunoglobulin V genes and ZAP-70 also experienced higher levels tyrosine phosphorylation of such cytosolic proteins following BCR ligation. Following BCR ligation, ZAP-70 underwent tyrosine phosphorylation and became associated with surface immunoglobulin and CD79b, arguing for the involvement of ZAP-70 in BCR signaling. These data indicate that expression of ZAP-70 is associated with enhanced signal transduction via the BCR complex, which may contribute to the more aggressive clinical course associated with CLL cells that express nonmutated immunoglobulin receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393534     DOI: 10.1182/blood-2002-06-1683

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  131 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

Review 2.  Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

Authors:  Leopold Sellner; Sascha Dietrich; Peter Dreger; Hanno Glimm; Thorsten Zenz
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 3.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

4.  Altered BCR signalling quality predisposes to autoimmune disease and a pre-diabetic state.

Authors:  Sebastian Königsberger; Jan Prodöhl; David Stegner; Vanessa Weis; Martin Andreas; Martin Stehling; Theresa Schumacher; Ruben Böhmer; Ina Thielmann; Judith M M van Eeuwijk; Bernhard Nieswandt; Friedemann Kiefer
Journal:  EMBO J       Date:  2012-06-22       Impact factor: 11.598

Review 5.  ZAP-70: an essential kinase in T-cell signaling.

Authors:  Haopeng Wang; Theresa A Kadlecek; Byron B Au-Yeung; Hanna E Sjölin Goodfellow; Lih-Yun Hsu; Tanya S Freedman; Arthur Weiss
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05       Impact factor: 10.005

6.  Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact.

Authors:  Wei-Gang Tong; William G Wierda; E Lin; Shao-Qing Kuang; B Nebiyou Bekele; Zeev Estrov; Yue Wei; Hui Yang; Michael J Keating; Guillermo Garcia-Manero
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

7.  Zap70 functions to maintain stemness of mouse embryonic stem cells by negatively regulating Jak1/Stat3/c-Myc signaling.

Authors:  Young Cha; Bo-hyun Moon; Mi-ok Lee; Hee-jin Ahn; Hye-jin Lee; Kyung-ah Lee; Albert J Fornace; Kwang-soo Kim; Hyuk-jin Cha; Kyung-soon Park
Journal:  Stem Cells       Date:  2010-09       Impact factor: 6.277

8.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

9.  E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.

Authors:  Jesús Duque-Afonso; Chiou-Hong Lin; Kyuho Han; Michael C Wei; Jue Feng; Jason H Kurzer; Corina Schneidawind; Stephen Hon-Kit Wong; Michael C Bassik; Michael L Cleary
Journal:  Cancer Res       Date:  2016-10-07       Impact factor: 12.701

10.  Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.

Authors:  Peter Ouillette; Samuel Fossum; Brian Parkin; Li Ding; Paula Bockenstedt; Ammar Al-Zoubi; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2010-01-19       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.